AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. HLXB
  4. [Form 4] Helix Acquisition Corp. II Insider Trading Activity

[Form 4] Helix Acquisition Corp. II Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Bihua Chen reported multiple ownership changes in BridgeBio Oncology Therapeutics, Inc. ("BBOT") tied to the closing of Helix Acquisition Corp. II's business combination and related subscription activity. On 08/11/2025, several Cormorant-managed funds purchased shares from the issuer: Fund III bought 760,496 shares, Fund V bought 639,110 shares, and Master Fund bought 5,598,425 shares, each at a purchase price of $10.7173 per share. These purchases were made under a subscription agreement with Helix.

Separately, the Sponsor forfeited shares for no consideration prior to closing: the forfeiture of 307,874 Class B ordinary shares and 152,940 shares of Common Stock is disclosed. The filing also explains that Helix's Class B shares converted into Class A shares and, following domestication, Class A shares converted one-for-one into the issuer's Common Stock. Ms. Chen is disclosed as manager with voting and investment discretion for the Sponsor and the Cormorant funds, while disclaiming beneficial ownership beyond any pecuniary interest.

Bihua Chen ha segnalato pi霉 cambi di propriet脿 in BridgeBio Oncology Therapeutics, Inc. ("BBOT") legati alla chiusura della business combination di Helix Acquisition Corp. II e all'attivit脿 di sottoscrizione correlata. In data 08/11/2025, diversi fondi gestiti da Cormorant hanno acquistato azioni dall'emittente: Fund III ha comprato 760,496 azioni, Fund V ha comprato 639,110 azioni e Master Fund ha comprato 5,598,425 azioni, ciascuna al prezzo di acquisto di $10.7173 per azione. Questi acquisti sono stati effettuati in base a un accordo di sottoscrizione con Helix.

Separatamente, lo Sponsor ha rinunciato a azioni senza ricevere alcun corrispettivo prima della chiusura: 猫 stata resa nota la rinuncia di 307,874 Class B ordinary shares e di 152,940 azioni di Common Stock. Il deposito spiega inoltre che le azioni Class B di Helix sono state convertite in azioni Class A e, a seguito della domestication, le azioni Class A sono state convertite uno a uno nel Common Stock dell'emittente. La sig.ra Chen 猫 indicata come manager con discrezionalit脿 di voto e di investimento per lo Sponsor e per i fondi Cormorant, pur dichiarando di non detenere la titolarit脿 beneficiaria oltre l'interesse pecuniario.

Bihua Chen inform贸 m煤ltiples cambios de titularidad en BridgeBio Oncology Therapeutics, Inc. ("BBOT") vinculados al cierre de la combinaci贸n de negocios de Helix Acquisition Corp. II y a la actividad de suscripci贸n relacionada. El 08/11/2025, varios fondos gestionados por Cormorant compraron acciones del emisor: Fund III compr贸 760,496 acciones, Fund V compr贸 639,110 acciones y Master Fund compr贸 5,598,425 acciones, cada una a un precio de compra de $10.7173 por acci贸n. Estas compras se realizaron en virtud de un acuerdo de suscripci贸n con Helix.

Por separado, el Sponsor renunci贸 a acciones sin contraprestaci贸n antes del cierre: se divulga la p茅rdida de 307,874 Class B ordinary shares y 152,940 acciones de Common Stock. La presentaci贸n tambi茅n explica que las acciones Clase B de Helix se convirtieron en acciones Clase A y, tras la domesticaci贸n, las acciones Clase A se convirtieron a raz贸n de una por una en el Common Stock del emisor. La Sra. Chen figura como gestora con discreci贸n de voto e inversi贸n para el Sponsor y los fondos de Cormorant, declarando a la vez no ostentar la titularidad beneficiaria m谩s all谩 de cualquier inter茅s pecuniario.

Bihua Chen電� Helix Acquisition Corp. II鞚� 靷梾 瓴绊暕 毵堦皭 氚� 甏�霠� 觳暯 頇滊彊瓿� 甏�霠暣 BridgeBio Oncology Therapeutics, Inc.("BBOT")鞚� 靻岇湢甓� 氤�霃� 鞐煬 瓯挫潉 氤搓碃頄堨姷雼堧嫟. 08/11/2025鞐� Cormorant臧� 鞖挫毄頃橂姅 鞐煬 韼�霌滉皜 氚滍枆靷攵�韯� 欤检嫕鞚� 毵れ垬頄堨姷雼堧嫟: Fund III電� 760,496欤茧ゼ 毵れ垬, Fund V電� 639,110欤茧ゼ 毵れ垬, Master Fund電� 5,598,425欤茧ゼ 毵れ垬, 臧� 欤茧嫻 毵れ瀰 臧�瓴╈潃 $10.7173鞓�鞀惦媹雼�. 鞚措煬頃� 毵れ垬電� Helix鞕赌鞚� 觳暯瓿勳暯鞐� 霐半ジ 瓴冹瀰雼堧嫟.

氤勲弰搿�, 鞀ろ彴靹�(Sponsor)電� 韥措歆� 鞝勳棎 雽�臧� 鞐嗢澊 欤检嫕鞚� 韽赴頄堨姷雼堧嫟: 307,874欤检潣 Class B ordinary shares鞕赌 152,940欤检潣 Common Stock鞚� 韽赴臧� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 霕愴暅 Helix鞚� Class B 欤检嫕鞚� Class A搿� 鞝勴櫂霅橃棃瓿�, domestication(雮搓淡頇�) 鞚错泟 Class A 欤检嫕鞚� 氚滍枆靷潣 Common Stock鞙茧 1雽�1 鞝勴櫂霅橃棃雼り碃 靹る獏頃╇媹雼�. Chen 鞌姅 鞀ろ彴靹滌櫠� Cormorant 韼�霌滌棎 雽�頃� 鞚橁舶甓� 氚� 韴瀽 鞛焿鞚� 臧�歆� 毵る媹鞝�搿� 旮办灛霅橃柎 鞛堨溂雮�, 旮堨爠鞝� 鞚挫澋鞚� 雱橂姅 鞁れ鞝� 靻岇湢甓岇潃 鞐嗢潓鞚� 攵�鞚疙晿瓿� 鞛堨姷雼堧嫟.

Bihua Chen a signal茅 plusieurs changements de propri茅t茅 dans BridgeBio Oncology Therapeutics, Inc. ("BBOT") li茅s 脿 la cl么ture de la combinaison d'entreprise de Helix Acquisition Corp. II et 脿 l'activit茅 de souscription associ茅e. Le 08/11/2025, plusieurs fonds g茅r茅s par Cormorant ont achet茅 des actions aupr猫s de l'茅metteur : Fund III a achet茅 760,496 actions, Fund V a achet茅 639,110 actions et Master Fund a achet茅 5,598,425 actions, chacune au prix d'achat de $10.7173 par action. Ces achats ont 茅t茅 effectu茅s en vertu d'un accord de souscription avec Helix.

S茅par茅ment, le Sponsor a abandonn茅 des actions sans contrepartie avant la cl么ture : la radiation de 307,874 Class B ordinary shares et de 152,940 actions de Common Stock est r茅v茅l茅e. Le d茅p么t explique 茅galement que les actions de Classe B de Helix ont 茅t茅 converties en actions de Classe A et, apr猫s la domestication, les actions de Classe A ont 茅t茅 converties une pour une en Common Stock de l'茅metteur. Mme Chen est indiqu茅e comme gestionnaire disposant du pouvoir de vote et de d茅cision d'investissement pour le Sponsor et les fonds Cormorant, tout en d茅clinant toute qualit茅 de propri茅taire b茅n茅ficiaire au-del脿 d'un simple int茅r锚t p茅cuniaire.

Bihua Chen meldete mehrere Eigentumswechsel bei BridgeBio Oncology Therapeutics, Inc. ("BBOT") im Zusammenhang mit dem Abschluss der Gesch盲ftsvereinigung von Helix Acquisition Corp. II und der damit verbundenen Zeichnungsaktivit盲t. Am 08/11/2025 kauften mehrere von Cormorant verwaltete Fonds Aktien vom Emittenten: Fund III erwarb 760,496 Aktien, Fund V erwarb 639,110 Aktien und Master Fund erwarb 5,598,425 Aktien, jeweils zu einem Kaufpreis von $10.7173 pro Aktie. Diese K盲ufe erfolgten aufgrund einer Zeichnungsvereinbarung mit Helix.

Separat hat der Sponsor vor dem Closing Aktien ohne Gegenleistung aufgegeben: offengelegt wird die Verwirkung von 307,874 Class B ordinary shares und 152,940 Aktien des Common Stock. Die Einreichung erkl盲rt au脽erdem, dass Helix' Class B-Aktien in Class A-Aktien umgewandelt wurden und nach der Domestizierung die Class A-Aktien eins zu eins in das Common Stock des Emittenten umgewandelt wurden. Frau Chen wird als Managerin mit Stimm- und Anlagevollmacht f眉r den Sponsor und die Cormorant-Fonds angegeben, erkl盲rt jedoch, keine wirtschaftliche Eigent眉merschaft 眉ber ein rein pekuni盲res Interesse hinaus zu beanspruchen.

Positive
  • Cormorant-managed funds materially increased positions by purchasing 760,496, 639,110, and 5,598,425 shares at $10.7173 per share, demonstrating significant affiliated investment.
  • Share class conversions and domestication were completed, converting Class B and Class A shares into the issuer's Common Stock on a one-for-one basis, simplifying capital structure.
  • Clear disclosure of voting and investment discretion indicates Ms. Chen retains governance influence through her managerial roles over Sponsor and the Cormorant funds.
Negative
  • Sponsor forfeited shares for no consideration (307,874 Class B shares and 152,940 Common Stock), which reduced certain Sponsor-held share counts.
  • Related-party complexity and disclaimers: the filing disclaims beneficial ownership by each fund except to the extent of any pecuniary interest, which may complicate assessment of true economic ownership and control.

Insights

TL;DR: Large institutional purchases total ~7.0M shares at $10.7173 signal material backing from Cormorant funds.

The Form 4 shows sizable capital commitment from Cormorant-managed vehicles: a 5,598,425-share purchase by the Master Fund plus purchases by Fund III and Fund V at $10.7173 per share. These transactions occurred in connection with the business combination and a subscription agreement, increasing affiliated ownership positions in BBOT. The disclosure of Sponsor forfeitures for no consideration reduces certain Sponsor-held shares while conversion and domestication steps standardized share classes into common stock. For investors, the transactions reflect active affiliated participation in the post-combination capitalization.

TL;DR: Disclosure clarifies control pathways but emphasizes disclaimers of beneficial ownership by related funds and manager.

The filing details the legal mechanics鈥擟lass B to Class A conversions, domestication, and one-for-one conversion into common stock鈥攁longside Sponsor forfeitures and subscriptions by affiliated funds. It explicitly states Ms. Chen's managerial voting and investment discretion for the Sponsor and the Cormorant funds, while also including standard disclaimers that each fund disclaims beneficial ownership except to the extent of any pecuniary interest. This is a routine but important governance disclosure that clarifies where voting power and economic interests reside after the business combination.

Bihua Chen ha segnalato pi霉 cambi di propriet脿 in BridgeBio Oncology Therapeutics, Inc. ("BBOT") legati alla chiusura della business combination di Helix Acquisition Corp. II e all'attivit脿 di sottoscrizione correlata. In data 08/11/2025, diversi fondi gestiti da Cormorant hanno acquistato azioni dall'emittente: Fund III ha comprato 760,496 azioni, Fund V ha comprato 639,110 azioni e Master Fund ha comprato 5,598,425 azioni, ciascuna al prezzo di acquisto di $10.7173 per azione. Questi acquisti sono stati effettuati in base a un accordo di sottoscrizione con Helix.

Separatamente, lo Sponsor ha rinunciato a azioni senza ricevere alcun corrispettivo prima della chiusura: 猫 stata resa nota la rinuncia di 307,874 Class B ordinary shares e di 152,940 azioni di Common Stock. Il deposito spiega inoltre che le azioni Class B di Helix sono state convertite in azioni Class A e, a seguito della domestication, le azioni Class A sono state convertite uno a uno nel Common Stock dell'emittente. La sig.ra Chen 猫 indicata come manager con discrezionalit脿 di voto e di investimento per lo Sponsor e per i fondi Cormorant, pur dichiarando di non detenere la titolarit脿 beneficiaria oltre l'interesse pecuniario.

Bihua Chen inform贸 m煤ltiples cambios de titularidad en BridgeBio Oncology Therapeutics, Inc. ("BBOT") vinculados al cierre de la combinaci贸n de negocios de Helix Acquisition Corp. II y a la actividad de suscripci贸n relacionada. El 08/11/2025, varios fondos gestionados por Cormorant compraron acciones del emisor: Fund III compr贸 760,496 acciones, Fund V compr贸 639,110 acciones y Master Fund compr贸 5,598,425 acciones, cada una a un precio de compra de $10.7173 por acci贸n. Estas compras se realizaron en virtud de un acuerdo de suscripci贸n con Helix.

Por separado, el Sponsor renunci贸 a acciones sin contraprestaci贸n antes del cierre: se divulga la p茅rdida de 307,874 Class B ordinary shares y 152,940 acciones de Common Stock. La presentaci贸n tambi茅n explica que las acciones Clase B de Helix se convirtieron en acciones Clase A y, tras la domesticaci贸n, las acciones Clase A se convirtieron a raz贸n de una por una en el Common Stock del emisor. La Sra. Chen figura como gestora con discreci贸n de voto e inversi贸n para el Sponsor y los fondos de Cormorant, declarando a la vez no ostentar la titularidad beneficiaria m谩s all谩 de cualquier inter茅s pecuniario.

Bihua Chen電� Helix Acquisition Corp. II鞚� 靷梾 瓴绊暕 毵堦皭 氚� 甏�霠� 觳暯 頇滊彊瓿� 甏�霠暣 BridgeBio Oncology Therapeutics, Inc.("BBOT")鞚� 靻岇湢甓� 氤�霃� 鞐煬 瓯挫潉 氤搓碃頄堨姷雼堧嫟. 08/11/2025鞐� Cormorant臧� 鞖挫毄頃橂姅 鞐煬 韼�霌滉皜 氚滍枆靷攵�韯� 欤检嫕鞚� 毵れ垬頄堨姷雼堧嫟: Fund III電� 760,496欤茧ゼ 毵れ垬, Fund V電� 639,110欤茧ゼ 毵れ垬, Master Fund電� 5,598,425欤茧ゼ 毵れ垬, 臧� 欤茧嫻 毵れ瀰 臧�瓴╈潃 $10.7173鞓�鞀惦媹雼�. 鞚措煬頃� 毵れ垬電� Helix鞕赌鞚� 觳暯瓿勳暯鞐� 霐半ジ 瓴冹瀰雼堧嫟.

氤勲弰搿�, 鞀ろ彴靹�(Sponsor)電� 韥措歆� 鞝勳棎 雽�臧� 鞐嗢澊 欤检嫕鞚� 韽赴頄堨姷雼堧嫟: 307,874欤检潣 Class B ordinary shares鞕赌 152,940欤检潣 Common Stock鞚� 韽赴臧� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 霕愴暅 Helix鞚� Class B 欤检嫕鞚� Class A搿� 鞝勴櫂霅橃棃瓿�, domestication(雮搓淡頇�) 鞚错泟 Class A 欤检嫕鞚� 氚滍枆靷潣 Common Stock鞙茧 1雽�1 鞝勴櫂霅橃棃雼り碃 靹る獏頃╇媹雼�. Chen 鞌姅 鞀ろ彴靹滌櫠� Cormorant 韼�霌滌棎 雽�頃� 鞚橁舶甓� 氚� 韴瀽 鞛焿鞚� 臧�歆� 毵る媹鞝�搿� 旮办灛霅橃柎 鞛堨溂雮�, 旮堨爠鞝� 鞚挫澋鞚� 雱橂姅 鞁れ鞝� 靻岇湢甓岇潃 鞐嗢潓鞚� 攵�鞚疙晿瓿� 鞛堨姷雼堧嫟.

Bihua Chen a signal茅 plusieurs changements de propri茅t茅 dans BridgeBio Oncology Therapeutics, Inc. ("BBOT") li茅s 脿 la cl么ture de la combinaison d'entreprise de Helix Acquisition Corp. II et 脿 l'activit茅 de souscription associ茅e. Le 08/11/2025, plusieurs fonds g茅r茅s par Cormorant ont achet茅 des actions aupr猫s de l'茅metteur : Fund III a achet茅 760,496 actions, Fund V a achet茅 639,110 actions et Master Fund a achet茅 5,598,425 actions, chacune au prix d'achat de $10.7173 par action. Ces achats ont 茅t茅 effectu茅s en vertu d'un accord de souscription avec Helix.

S茅par茅ment, le Sponsor a abandonn茅 des actions sans contrepartie avant la cl么ture : la radiation de 307,874 Class B ordinary shares et de 152,940 actions de Common Stock est r茅v茅l茅e. Le d茅p么t explique 茅galement que les actions de Classe B de Helix ont 茅t茅 converties en actions de Classe A et, apr猫s la domestication, les actions de Classe A ont 茅t茅 converties une pour une en Common Stock de l'茅metteur. Mme Chen est indiqu茅e comme gestionnaire disposant du pouvoir de vote et de d茅cision d'investissement pour le Sponsor et les fonds Cormorant, tout en d茅clinant toute qualit茅 de propri茅taire b茅n茅ficiaire au-del脿 d'un simple int茅r锚t p茅cuniaire.

Bihua Chen meldete mehrere Eigentumswechsel bei BridgeBio Oncology Therapeutics, Inc. ("BBOT") im Zusammenhang mit dem Abschluss der Gesch盲ftsvereinigung von Helix Acquisition Corp. II und der damit verbundenen Zeichnungsaktivit盲t. Am 08/11/2025 kauften mehrere von Cormorant verwaltete Fonds Aktien vom Emittenten: Fund III erwarb 760,496 Aktien, Fund V erwarb 639,110 Aktien und Master Fund erwarb 5,598,425 Aktien, jeweils zu einem Kaufpreis von $10.7173 pro Aktie. Diese K盲ufe erfolgten aufgrund einer Zeichnungsvereinbarung mit Helix.

Separat hat der Sponsor vor dem Closing Aktien ohne Gegenleistung aufgegeben: offengelegt wird die Verwirkung von 307,874 Class B ordinary shares und 152,940 Aktien des Common Stock. Die Einreichung erkl盲rt au脽erdem, dass Helix' Class B-Aktien in Class A-Aktien umgewandelt wurden und nach der Domestizierung die Class A-Aktien eins zu eins in das Common Stock des Emittenten umgewandelt wurden. Frau Chen wird als Managerin mit Stimm- und Anlagevollmacht f眉r den Sponsor und die Cormorant-Fonds angegeben, erkl盲rt jedoch, keine wirtschaftliche Eigent眉merschaft 眉ber ein rein pekuni盲res Interesse hinaus zu beanspruchen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chen Bihua
(Last) (First) (Middle)
C/O HELIX ACQUISITION CORP. II
200 CLARENDON STREET, 52ND FLOOR
(Street)
BOSTON MA 02116
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/11/2025 M(3) 4,172,126 A (3) 4,681,126 I Via Helix Holdings II LLC(9)
Common Stock 08/11/2025 D(4) 152,940 D $0 4,528,186 I Via Helix Holdings II LLC(9)
Common Stock 08/11/2025 A(5) 760,496 A $10.7173 2,187,536 I Via Fund III(10)
Common Stock 08/11/2025 A(6) 639,110 A $10.7173 1,542,710 I Via Fund V(10)
Common Stock 08/11/2025 A(7) 5,598,425 A $10.7173 5,667,785 I Via Master Fund(10)
Common Stock 08/11/2025 A(8) 1,905,046 A (8) 1,905,046 I Via Fund IV(10)
Common Stock 08/11/2025 A(8) 1,762,760 A (8) 3,305,470 I Via Fund V(10)
Common Stock 08/11/2025 A(8) 284,571 A (8) 5,952,356 I Via Master Fund(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B ordinary shares (2) 08/11/2025 D(1) 307,874 (2) (2) Class A ordinary shares 307,874 $0 4,172,126 I See footnote(9)
Class B ordinary shares (2) 08/11/2025 M(3) 4,172,126 (2) (2) Class A ordinary shares 4,172,126 (3) 0 I See footnote(9)
Explanation of Responses:
1. In connection with and prior to the closing of the business combination (the "Business Combination") between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc. ("Legacy BBOT"), Helix Holdings II LLC (the "Sponsor") forfeited 307,874 Helix Class B ordinary shares for no consideration pursuant to the terms of the Sponsor Support Agreement dated February 28, 2025, between Sponsor, Helix, and Legacy BBOT (the "Sponsor Support Agreement").
2. The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading "Description of Securities" in Helix's registration statement on Form S-1 (File No. 333-276591).
3. In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis.
4. In connection with and immediately prior to the closing of the Business Combination, the Sponsor forfeited 152,940 shares of Common Stock for no consideration, pursuant to the terms of the Sponsor Support Agreement.
5. In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of a subscription agreement dated February 28, 2025 between Helix and Cormorant Asset Management, LP (the "Subscription Agreement"), Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 760,496 shares of Common Stock at a purchase price of $10.7173 per share.
6. In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 639,110 shares of Common Stock at a purchase price of $10.7173 per share.
7. In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 5,598,425 shares of Common Stock at a purchase price of $10.7173 per share.
8. Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the "Business Combination Agreement"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP ("Fund IV"), received as consideration therefor, shares of common stock of the Issuer.
9. Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly.
10. Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Remarks:
Ms. Chen serves on the Board of Directors of the Issuer. Sponsor and the Cormorant Funds may be deemed to be directors by deputization as a result of the service of Ms. Chen.
/s/ Bihua Chen 08/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Bihua Chen report on Form 4 for HLXB/BBOT?

The Form 4 reports transactions on 08/11/2025: Cormorant-managed funds purchased 760,496 (Fund III), 639,110 (Fund V), and 5,598,425 (Master Fund) shares at $10.7173 per share; the Sponsor forfeited 307,874 Class B shares and 152,940 Common Stock for no consideration.

How many shares did the Cormorant Master Fund buy and at what price?

The Cormorant Global Healthcare Master Fund, LP purchased 5,598,425 shares at a purchase price of $10.7173 per share.

What forfeitures did the Sponsor report in the filing?

The Sponsor forfeited 307,874 Helix Class B ordinary shares and 152,940 shares of Common Stock for no consideration pursuant to the Sponsor Support Agreement.

Does Bihua Chen have voting or investment control over the reported shares?

Yes. The filing states Ms. Chen is the manager of the Sponsor and the general/ managing member of entities controlling the Cormorant funds and therefore has voting and investment discretion over the shares held by those entities.

Did the filing explain conversion of different share classes?

Yes. The filing discloses that Helix Class B shares converted into Class A shares and, following domestication, Class A shares converted one-for-one into the issuer's Common Stock.
Stock HLXB logo
Helix Acqsn II

NASDAQ:HLXB

HLXB Rankings

#3992 Ranked by Market Cap
N/A Ranked by Dividends

HLXB Latest News

Aug 6, 2025
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
Jul 11, 2025
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination
Feb 28, 2025
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3K伪-Targeting Medicines
Feb 14, 2024
Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter';s Option to Purchase Additional Shares
Feb 9, 2024
Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering

HLXB Latest SEC Filings

Aug 12, 2025
[8-K] Helix Acquisition Corp. II Reports Material Event
Aug 13, 2025
[SCHEDULE 13D/A] Helix Acquisition Corp. II SEC Filing
Aug 11, 2025
[Form 3] Helix Acquisition Corp. II Initial Statement of Beneficial Ownership
Aug 11, 2025
[Form 4] Helix Acquisition Corp. II Insider Trading Activity
Aug 11, 2025
[Form 4] Helix Acquisition Corp. II Insider Trading Activity

HLXB Stock Data

232.74M
10.02M
44.89%
87.34%
0.02%
Shell Companies
Pharmaceutical Preparations
United States
BOSTON